BACKGROUND: Recent studies have shown that monocytes in human peripheral blood are heterogeneous. The clinical significance of 2 distinct monocyte subsets as a marker of late in-stent restenosis (ISR) following implantation of bare-metal stents (BMSs) in patients with acute myocardial infarction (AMI) was examined. METHODS AND RESULTS: Seventy-one consecutive patients with AMI who underwent BMS implantation were enrolled in the study. Peripheral blood was collected 12 days after AMI onset. Two distinct monocyte subsets (CD14(+)CD16(-)CCR2(+) and CD14(+)CD16(+)CX3CR1(+)) were measured by flow cytometry. All patients underwent angiography at a scheduled follow up after 9 months. CD14(+)CD16(+)CX3CR1(+) monocyte subset counts were significantly higher in patients with restenosis than in patients without restenosis, whereas neither the total monocytes nor the CD14(+)CD16(-)CCR2(+) subset counts differed significantly between the 2 groups of patients. There was also a significant positive correlation between the CD14(+)CD16(+)CX3CR1(+) monocyte counts and angiographic late lumen loss. In multivariate analysis, the CD14(+)CD16(+)CX3CR1(+) monocyte count was an independent predictor for in-stent late lumen loss. CONCLUSIONS: CD14(+)CD16(+)CX3CR1(+) monocytes might have a role in ISR following coronary BMS implantation in patients with AMI.
BACKGROUND: Recent studies have shown that monocytes in human peripheral blood are heterogeneous. The clinical significance of 2 distinct monocyte subsets as a marker of late in-stent restenosis (ISR) following implantation of bare-metal stents (BMSs) in patients with acute myocardial infarction (AMI) was examined. METHODS AND RESULTS: Seventy-one consecutive patients with AMI who underwent BMS implantation were enrolled in the study. Peripheral blood was collected 12 days after AMI onset. Two distinct monocyte subsets (CD14(+)CD16(-)CCR2(+) and CD14(+)CD16(+)CX3CR1(+)) were measured by flow cytometry. All patients underwent angiography at a scheduled follow up after 9 months. CD14(+)CD16(+)CX3CR1(+) monocyte subset counts were significantly higher in patients with restenosis than in patients without restenosis, whereas neither the total monocytes nor the CD14(+)CD16(-)CCR2(+) subset counts differed significantly between the 2 groups of patients. There was also a significant positive correlation between the CD14(+)CD16(+)CX3CR1(+) monocyte counts and angiographic late lumen loss. In multivariate analysis, the CD14(+)CD16(+)CX3CR1(+) monocyte count was an independent predictor for in-stent late lumen loss. CONCLUSIONS:CD14(+)CD16(+)CX3CR1(+) monocytes might have a role in ISR following coronary BMS implantation in patients with AMI.
Authors: Elena V Zholdybayeva; Yerkebulan A Talzhanov; Akbota M Aitkulova; Pavel V Tarlykov; Gulmira N Kulmambetova; Aisha N Iskakova; Aliya U Dzholdasbekova; Olga A Visternichan; Dana Zh Taizhanova; Yerlan M Ramanculov Journal: Hum Genomics Date: 2016-06-08 Impact factor: 4.639
Authors: Gunnar H Heine; Alberto Ortiz; Ziad A Massy; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Gianfranco Parati; Rosa Sicari; Carmine Zoccali; Danilo Fliser Journal: Nat Rev Nephrol Date: 2012-03-13 Impact factor: 28.314
Authors: Jing Li; Andreas J Flammer; Martin K Reriani; Yoshiki Matsuo; Rajiv Gulati; Paul A Friedman; Randal J Thomas; Nicole P Sandhu; Lilach O Lerman; Amir Lerman Journal: Circ J Date: 2012-12-06 Impact factor: 2.993